Bayer Ag · XETR:BAYN

Bayer — 23rd European Society of Retina Specialists (EURETINA) Congress 2023

8 slides from Bayer's conference presentation, October 2023

  1. Slide 1: Early Fluid Resolution Association with Treatment Interval Maintenance at Week 48 in nAMD

    Early Fluid Resolution Association with Treatment Interval Maintenance at Week 48 in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration Receiving Aflibercept 8 mg: Post Hoc Analysis of the Phase 3 PULSAR Trial Javier Zarranz-Ventura,1 Varun Chaudhary,2 Sergio Leal,3 Tobias Ma

  2. Slide 2: Disclosures

    Disclosures nAMD • JZV: Receives grants from AbbVie, Allergan Inc., Bayer, Novartis, and Roche; is a member of scientific advisory boards for AbbVie, Allergan Inc., Bayer, Novartis, and Roche; is a speaker for Alcon, Alimera Sciences, Allergan Inc., AbbVie, Bausch + Lomb, Bayer, Brill Pharma, D.O.R.

  3. Slide 3: PULSAR Study Design and Dosing Schedule

    PULSAR Study Design and Dosing Schedule nAMD 96-week, multicenter, randomized, double-masked study in patients with treatment-naïve nAMD Randomized at baseline 1 (2q8) : 1 (8q12) : 1 (8q16)

  4. Slide 4: 48-Week Visual and Anatomic Outcomes

    48-Week Visual and Anatomic Outcomes nAMD

  5. Slide 5: Analysis of Early Fluid Resolution Associated with Dosing Interval

    Analysis of Early Fluid Resolution Associated with Dosing Interval nAMD Objective: To evaluate if early fluid resolution during the initial treatment phase may serve as a biomarker to predict the likelihood of patients with nAMD achieving extended dosing intervals with aflibercept 8 mg Methods: The

  6. Slide 6: Early Fluid Resolution: A Potential Biomarker

    Early Fluid Resolution: A Potential Biomarker nAMD

  7. Slide 7: Patients Maintaining ≥Q12- and Q16-Week Dosing Intervals at Week 48 Based on Early Fluid Status

    Patients Maintaining ≥Q12- and Q16-Week Dosing Intervals at Week 48 Based on Early Fluid Status: Aflibercept 8q16 Treatment Group nAMD

  8. Slide 8: Conclusions

    Conclusions wy Fluid Free at Week 4 # ~ Cc Patients who were Never Fluid Free > (n=1828) During the Initial Treatment Phase (n=50?) Ne Ne « Approximately 80% of patients who were fluid free at Week 4 maintained a Q16 interval until Week 48 compared with 66% of patients who had never been fluid free

Bayer — 23rd European Society of Retina Specialists (EURETINA) Congress 2023 on 6ix